Areva Med

Areva Med has commenced lead-212 production at its new domestic distribution and purification unit (DDPU) in Plano, Texas.

The lead-212 is a rare metal used in targeted alpha therapy (TAT), in an increasing number of studies to target cancer cells, while limiting the impact on nearby healthy cells.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Areva Med said that it has developed a unique process to extract lead-212.

With increased production capacities, Areva Med will accelerate the development of TATs using lead-212 to combat cancer.

The new facility will allow Areva Med to expand the range and increase the quality of products and services for its American partners and customers.

Areva Med CEO Patrick Bourdet said: "Our new modular and unique US plant will allow us to quickly expand our cancer therapy pipeline and increase collaboration within the entire continent."

Construction on the facility commenced in September last year.

The DDPU will house the company’s US activities in a centralised modular plant, which will also hold Areva Med subsidiary Macrocyclics’ operations.

Macrocyclics is involved in the design and manufacturing of chelating agents for nuclear medicine.

"Our new modular and unique US plant will allow us to quickly expand our cancer therapy pipeline and increase collaboration within the entire continent."

Plano Mayor Harry LaRosiliere said: "It is always a great day when we can welcome to the City of Plano a US Headquarters and international company such as Areva Med, which does invaluable work in the field of cancer research.

"We look forward to their success and future expansion as they continue to develop innovative cancer therapies."

The company already operates its first-of-a-kind high-purity lead-212 production facility in France since 2013.

Areva Med collaborates with world-renowned scientific partners, and formed a strategic global alliance with Roche in 2012, to create a new advanced alpha radioimmunotherapy platform.

Image: Plano Mayor Harry LaRosiliere and Areva Med CEO Patrick Bourdet inaugurate second lead-212 production facility. Photo: courtesy of Jim Herndon.